VICTORIS
Budget Express 2026

co-presented by

  • LIC
  • JIO BlackRock

ASSOCIATE SPONSORS

  • Sunteck
  • SBI
  • Emirates
  • Dezerv
Parallel Income Plan 2026
Parallel Income Plan 2026

Regulatory defaults unfortunate but inexcusable: Wockhardt

Wockhardt's injectible facility in Waluj is under an import ban from the US and the UK drug regulator since May 2013. And the company says it is seeking a meeting with the USFDA & UK regulator MHRA to discuss progress.

September 03, 2013 / 18:25 IST

Chairman of the drug firm Wockhardt, which has been struggling with quality issues at two of its manufacturing plants, says the company has already responded to USFDA's Form 483 observations on its Chikalthana Plant and is awaiting the regulator’s response, reports CNBC-TV18's Archana Shukla. 

In July 2013, USFDA had made observations on company’s manufacturing compliances at the Chikalthana facility, the second facility to come under the regulators scanner.

Also read: Sharma says govt looking at concerns over FDI in pharma  

The company’s injectible facility in Waluj is under an import ban from the US and the UK drug regulator since May 2013. And the company says it is seeking a meeting with the USFDA & UK regulator MHRA to discuss progress. 

Habil Khorakiwala, addressing the company’s shareholders at the AGM said the company has put corrective and pre-emptive steps in place to resolve the issues. “The regulatory defaults were unfortunate but inexcusable,” he said.

The company now has a new Head of Quality. The drug firm has appointed global advisors and consultants to help adhere to GMP practices and has initiated internal & external compliances training programs. These processes would expand to cover not only the affected sites but all of Wockhardt's manufacturing units, he said. “We are not looking at these as one plant problem but want to make systems integrated and quality systems common across manufacturing plants,” Khorakiwala said.

The company is now shifting all new drug filings to its new facility in Shendra, Maharashtra, which is expecting USFDA inspections in October this year. But on plans of shifting existing products from Waluj to its Chikalthana plant, the company says it is revisiting those plans owing to the USFDA’s Form 483.

However, Khorakiwala said that in recent inspection by the Indian drug regulator, both its Waluj & Chikalthana plants were cleared for Indian supplies. “The inspectors did not find any major issue and since they did not ask us to stop supplies I believe all is correct there.”

first published: Sep 3, 2013 05:13 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
CloseParallel Income Plan 2026